Provided by Tiger Trade Technology Pte. Ltd.

SBP GROUP

5.580
-0.130-2.28%
Volume:35.27M
Turnover:195.82M
Market Cap:104.25B
PE:36.74
High:5.630
Open:5.605
Low:5.440
Close:5.710
52wk High:8.335
52wk Low:4.136
Shares:18.68B
HK Float Shares:18.68B
Volume Ratio:0.58
T/O Rate:0.19%
Dividend:0.12
Dividend Rate:2.15%
EPS(LYR):0.152
ROE:14.07%
ROA:7.51%
PB:2.74
PE(LYR):36.74
PS:2.64

Loading ...

Sino Biopharma Unit Gets Breakthrough Therapy Designation for Cancer Drug in China

MT Newswires Live
·
Aug 03

SBP Group's Third Breakthrough Therapy Designation for TQB2102 Strengthens Its Position in HER2-Targeted Cancer Treatments

Stock News
·
Aug 03

Sino Biopharmaceutical - Tqb2102 Her2 Bispecific ADC Granted Breakthrough Therapy Designation by Cde for Her2-Low Breast Cancer

THOMSON REUTERS
·
Aug 03

Sino Biopharmaceutical Stock Falls 1.7% in Hong Kong, Underperforms Competitors

Dow Jones
·
Aug 03

SBP GROUP to Present 21 Oncology Studies—Five as Oral Sessions—at 2026 CSCO Annual Meeting

Bulletin Express
·
Jul 30

SBP Group Unveils 21 Studies for Upcoming Oncology Conference, Including 5 Oral Presentations

Stock News
·
Jul 30

Stock Track | SBP GROUP Plummets 5.35% Intraday as Pharmaceutical Sector Faces Broad Selling Pressure

Stock Track
·
Jul 30

Movement Alert|SBP GROUP Falls 3.06% in Regular Trading, Pharmaceutical Sector Under Broad Selling Pressure

Market Focus
·
Jul 30

Sino Biopharmaceutical Stock Rises 2.8% in Hong Kong

Dow Jones
·
Jul 29

Chinese Biopharma Forms Strategic Joint Venture with Tempo Scan to Boost Access to Innovative Drugs in Indonesia

Stock News
·
Jul 27

Sino Biopharmaceutical Forms 51:49 JV With Tempo Scan to Accelerate Innovative Drug Access in Indonesia

Bulletin Express
·
Jul 27

Sino Biopharmaceutical - Enters Joint Venture with Tempo Scan to Establish PT Tempo Cttq Biopharmaceutical Indonesia

THOMSON REUTERS
·
Jul 27

Sino Biopharmaceutical - Holds 51% Stake in Joint Venture, Tempo Scan Holds 49%

THOMSON REUTERS
·
Jul 27

Sino Biopharmaceutical - Joint Venture to Focus on Regulatory, Clinical, Commercialization, and Local Manufacturing in Indonesia

THOMSON REUTERS
·
Jul 27

Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$8.26 From HK$8.67, Keeps at Buy

MT Newswires Live
·
Jul 27

Sino Biopharma Unit Gets Trial Approval for Chronic Hepatitis B Drug in China

MT Newswires Live
·
Jul 23

SBP Group obtains NMPA clearance to begin clinical trial of PreS1-targeting IM-101 for chronic hepatitis B

Bulletin Express
·
Jul 23

IM-101 Injection, a PreS1-Targeting Novel Therapy, Receives NMPA Clearance for Clinical Trials in Chronic Hepatitis B

Stock News
·
Jul 23

Sino Biopharm Says China NMPA Clears Im-101 Hepatitis B Drug for Clinical Trial

Reuters
·
Jul 23

Sino Biopharmaceutical - Enters Strategic Collaboration with GSK for Bepirovirsen Launch in China

THOMSON REUTERS
·
Jul 23